Madrigal Pharmaceuticals to Report Q3 Results November 3
The biopharmaceutical company will share its financial and operating results before U.S. markets open that morning.
Updated on Oct. 20, 2026 in Corporate Finance
Live Poll
Do you trust that companies provide clear and timely financial information to individual investors?
Madrigal Pharmaceuticals is scheduled to release its third-quarter 2026 financial results on November 3, 2026. Following the report, the company will host a live webcast at 8 a.m. Eastern Time.
Why it matters
Investors look to these quarterly reports to gauge the financial health and operational progress of the company as it commercializes its liver-directed therapy.
The company will provide data for the 3rd quarter reporting period during a live webcast starting at 8 a.m. Eastern Time. Participants are advised to register 15 minutes before the call begins.
The players
Madrigal Pharmaceuticals
This biopharmaceutical company focuses on developing innovative therapies for non-alcoholic steatohepatitis.
The details
Headquartered in Conshohocken, Pennsylvania, Madrigal Pharmaceuticals produces Rezdiffra, an oral liver-directed THR-β agonist. Rezdiffra currently stands as the first FDA and European Commission approved medication for MASH with moderate to advanced fibrosis, while a Phase 3 outcomes trial for compensated MASH cirrhosis continues.
Timeline
November 3, 2026: Third-quarter 2026 financial results are released.
November 3, 2026: Live webcast begins at 8 a.m. Eastern Time.
Market Landscape
The report follows the progress of the ongoing Phase 3 outcomes trial for compensated MASH cirrhosis, providing insight into the company's fiscal runway. This financial disclosure updates the company's standing as it works to maintain its competitive position in the liver-directed therapy market.
Shareholders and potential investors should monitor the report for updates on the commercial adoption of Rezdiffra and the financial implications of ongoing clinical trials. These disclosures may influence market sentiment regarding the company's future growth trajectory.
The takeaway
This report represents a critical check-in for stakeholders interested in the commercial scaling of the company's lead MASH treatment. Interested parties should ensure they have the necessary registration to access the morning webcast.
Further reading
For more on industry performance, visit the Corporate Finance section.
More information
View the Madrigal Pharmaceuticals investor relations page for official company filings.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that companies provide clear and timely financial information to individual investors?
